

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Jing S. Belfield
Type or print name

J. S. Belfield
Signature

6/28/04
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**IN RE APPLICATION OF****QUAN ET AL.****APPLICATION NO: 10/796,396****FILED: MARCH 9, 2004****FOR: TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE
PROTEASE INHIBITORS**

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3791




Jing S. Belfield
Agent for Applicants
Reg. No. 45,914

Date: 6/29/04

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)


 ATTY. DOCKET NO.
 PH7493 NP
 APPLICATION NO.
 10/796,396
 APPLICANT
 QUAN ET AL.
 FILING DATE
 MARCH 9, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Bouma, B.N. et al., "Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)", Thrombosis Research, Vol. 101, pp. 329-354 (2001)
	AS	Colman, R.W., Chapter 6: "Contact Activation Pathway: Inflammatory, Fibrinolytic, Anticoagulant, Antiadhesive, and Antiangiogenic Activities", Hemostasis and Thrombosis: Basic Principles and Clinical Practice, Fourth Edition, Lippincott Williams & Wilkins, publ., pp. 103-121 (2001)
	AT	Gailani, D., "Activation of Factor IX by Factor XIa", Trends Cardiovasc. Med., Vol. 10, No. 5, pp. 198-204 (2000)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
PH7493 NP
APPLICATION NO.
10/796,396
APPLICANT
QUAN ET AL.
FILING DATE
MARCH 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	2AA	Gailani, D., "Gene Targeting in Hemostasis. Factor XI", <i>Frontiers in Bioscience</i> , Vol. 6, pp. d201-d207 (2001)
	2AB	Gailani, D. et al., "A murine model of factor XI deficiency", <i>Blood Coagulation and Fibrinolysis</i> , Vol. 8, pp. 134-144 (1997)
	2AC	Meijers, J.C.M. et al., "High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis", <i>The New England Journal of Medicine</i> , Vol. 342, No. 10, pp. 696-701 (2000)
	2AD	Minnema, M.C. et al., "Activation of Clotting Factors XI and IX in Patients With Acute Myocardial Infarction", <i>Arterioscler. Thromb. Vasc. Biol.</i> , Vol. 20, pp. 2489-2493 (2000)
	2AE	Murakami, T. et al., "Evaluation of Factor XIa- α_1 -Antitrypsin in Plasma, a Contract Phase-Activated Coagulation Factor-Inhibitor Complex, in Patients With Coronary Artery Disease", <i>Arterioscler. Thromb. Vasc. Biol.</i> , Vol. 15, No. 8, pp. 1107-1113 (1995)
	2AF	Schmaier, A.H., Chapter 5: "Contact Activation", <i>Thrombosis and Hemorrhage</i> , Williams & Wilkins, publ., Loscalzo, J. et al., eds., pp. 105-127 (1998)
	2AG	Walsh, P.N., "Platelets and Factor XI Bypass the Contact System of Blood Coagulation", <i>Thrombosis and Haemostasis</i> , Vol. 82, No. 2, pp. 234-242 (1999)
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.